WO2012067447A3 - 스티락스리그놀리드 ａ 또는 이의 비당체를 유효성분으로 함유하는 천식의 예방 또는 치료용 조성물 - Google Patents

스티락스리그놀리드 ａ 또는 이의 비당체를 유효성분으로 함유하는 천식의 예방 또는 치료용 조성물 Download PDF

Info

Publication number
WO2012067447A3
WO2012067447A3 PCT/KR2011/008805 KR2011008805W WO2012067447A3 WO 2012067447 A3 WO2012067447 A3 WO 2012067447A3 KR 2011008805 W KR2011008805 W KR 2011008805W WO 2012067447 A3 WO2012067447 A3 WO 2012067447A3
Authority
WO
WIPO (PCT)
Prior art keywords
styraxlignolide
aglycone
inhibiting
preventing
active ingredient
Prior art date
Application number
PCT/KR2011/008805
Other languages
English (en)
French (fr)
Other versions
WO2012067447A2 (ko
Inventor
안경섭
장하영
오세량
이형규
권옥경
김세미
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Priority to EP11842263.3A priority Critical patent/EP2641604B1/en
Priority to CN201180065080.3A priority patent/CN103313717B/zh
Priority to US13/885,986 priority patent/US8980846B2/en
Priority to JP2013539765A priority patent/JP5806324B2/ja
Publication of WO2012067447A2 publication Critical patent/WO2012067447A2/ko
Publication of WO2012067447A3 publication Critical patent/WO2012067447A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

본 발명은 스티락스리그놀리드(Styraxlignolide) A 또는 이의 비당체(aglycone)를 유효성분으로 함유하는 천식의 예방 또는 치료용 약학적 조성물에 관한 것으로, 구체적으로 상기 스티락스리그놀리드 A 화합물은 때죽나무(Styrax japonica)의 줄기 및 껍질에서 분리한 것으로서, 상기 스티락스리그놀리드 A, 또는 이의 비당체로서 안전성을 증가시킨 호모에고놀(homoegonol)은 천식 유도 마우스 모델에서 체중 감소 및 기도과민성을 경감시키고, 기도내 활성 산소 발생량을 억제시키며, 혈청 및 기관지폐포 세척액내 IgE, TGF-β1 및 IL-17 생성을 억제시킬 뿐만 아니라, 기관지내 염증세포 침윤을 억제하고, 점액마개(mucous plug) 및 기저막하부 섬유화(subepithelial fibrosis)를 억제시키는 효과를 나타내므로, 상기 스티락스리그놀리드 또는 호모에고놀은 기도개형이 진행된 기관지 천식의 예방 또는 치료를 위한 약학적 조성물의 유효성분으로서 유용하게 이용될 수 있다.
PCT/KR2011/008805 2010-11-17 2011-11-17 스티락스리그놀리드 ａ 또는 이의 비당체를 유효성분으로 함유하는 천식의 예방 또는 치료용 조성물 WO2012067447A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP11842263.3A EP2641604B1 (en) 2010-11-17 2011-11-17 Composition containing styraxlignolide a or the aglycone thereof as an active ingredient for preventing or treating asthma
CN201180065080.3A CN103313717B (zh) 2010-11-17 2011-11-17 用于对哮喘进行预防或治疗的、包含styraxlignolide A或其苷元作为活性成分的组合物
US13/885,986 US8980846B2 (en) 2010-11-17 2011-11-17 Composition containing styraxlignolide A or the aglycone thereof as an active ingredient for preventing or treating asthma
JP2013539765A JP5806324B2 (ja) 2010-11-17 2011-11-17 スチラキスリグノリドａまたはそのアグリコンを有効成分として含む喘息の予防または治療用組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2010-0114672 2010-11-17
KR20100114672 2010-11-17
KR1020110120160A KR101322391B1 (ko) 2010-11-17 2011-11-17 스티락스리그놀리드 ａ 또는 이의 비당체를 유효성분으로 함유하는 천식의 예방 또는 치료용 조성물
KR10-2011-0120160 2011-11-17

Publications (2)

Publication Number Publication Date
WO2012067447A2 WO2012067447A2 (ko) 2012-05-24
WO2012067447A3 true WO2012067447A3 (ko) 2012-07-12

Family

ID=46874304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/008805 WO2012067447A2 (ko) 2010-11-17 2011-11-17 스티락스리그놀리드 ａ 또는 이의 비당체를 유효성분으로 함유하는 천식의 예방 또는 치료용 조성물

Country Status (6)

Country Link
US (1) US8980846B2 (ko)
EP (1) EP2641604B1 (ko)
JP (1) JP5806324B2 (ko)
KR (1) KR101322391B1 (ko)
CN (1) CN103313717B (ko)
WO (1) WO2012067447A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6343013B2 (ja) * 2014-01-28 2018-06-13 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｂｉｏｓｃｉｅｎｃｅ Ａｎｄ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 新規２−フェニルベンゾフラン誘導体又はその薬学的に許容される塩、その生産方法、及び炎症性疾患を予防又は治療するための、活性成分としてそれを含む医薬組成物
KR101718938B1 (ko) * 2014-03-13 2017-03-23 한국생명공학연구원 벤조퓨란계 화합물 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 천식 예방 및 치료용 조성물
WO2015147597A1 (ko) * 2014-03-27 2015-10-01 한국생명공학연구원 호모에고놀을 유효성분으로 함유하는 만성폐쇄성 폐질환 예방 및 치료용 약학적 조성물
CN106176967B (zh) * 2016-07-19 2017-09-01 中南民族大学 一种舒张气管平滑肌的药物组合物
JP2019533149A (ja) * 2016-09-23 2019-11-14 ヴェンタナ メディカル システムズ， インク． 腫瘍試料中の細胞外マトリックスバイオマーカーをスコアリングするための方法及びシステム

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MIN, BYEONG SEON ET AL.: "Anti-Complement Activity of Norlignans and Terpenes from the Stem Bark of Styrax japonica", PLANTA MED., vol. 70, no. 12, 2004, pages 1210 - 1215, XP055111048 *
PAULETTI, P. M. ET AL.: "The Styracaceae", BRAZILIAN JOURNAL OF PHARMACOGNOSY, vol. 16, no. 4, 2006, pages 576 - 590, XP055111056 *
See also references of EP2641604A4 *
WILLS-KARP, M.: "Complement Activation Pathways, A Bridge between Innate and Adaptive Immune Responses in Asthma", PROC. AM. THORAC. SOC., vol. 4, no. 3, 1 July 2007 (2007-07-01), pages 247 - 251, XP055111049 *

Also Published As

Publication number Publication date
EP2641604A4 (en) 2014-06-18
JP5806324B2 (ja) 2015-11-10
CN103313717B (zh) 2015-04-29
US8980846B2 (en) 2015-03-17
CN103313717A (zh) 2013-09-18
EP2641604A2 (en) 2013-09-25
KR20120089784A (ko) 2012-08-13
US20130244959A1 (en) 2013-09-19
KR101322391B1 (ko) 2013-10-29
EP2641604B1 (en) 2016-09-07
WO2012067447A2 (ko) 2012-05-24
JP2013544252A (ja) 2013-12-12

Similar Documents

Publication Publication Date Title
WO2012067447A3 (ko) 스티락스리그놀리드 ａ 또는 이의 비당체를 유효성분으로 함유하는 천식의 예방 또는 치료용 조성물
NZ707551A (en) Prostacyclin compositions and methods for using the same
WO2012031603A3 (en) Airway administration of angiogenesis inhibitors
MX351781B (es) Composiciones farmaceuticas inhalables.
PL2670395T3 (pl) Suche proszkowe formulacje cząstek, które zawierają dwa lub więcej składników aktywnych do leczenia obturacyjnych lub zapalnych chorób dróg oddechowych
WO2008064357A3 (en) Nanoparticles for protection of cells from oxidative stress
WO2012016889A3 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
WO2011158042A3 (en) Ureido- pyrazole derivatives for use in the treatment of rhinovirus infections
IT1393045B1 (it) Composizioni contenenti monogliceridi di acidi organici da c1 a c7 e glicerolo, loro preparazione ed uso come antibatterici in zootecnia.
WO2009099998A3 (en) Therapeutic treatment for lung conditions
WO2010079914A3 (en) A composition comprising the compound isolated from the extract of rubiae radix for preventing and treating inflammatory diseases
WO2011149711A3 (en) Azeotrope-like composition of hexafluoropropane, hexafluoropropene and hydrogen fluoride
PE20142435A1 (es) Particulas inhalables que comprenden tiotropio
WO2014184145A3 (en) Spinel forming refractory compositions, their method of production and use thereof
WO2014053401A3 (en) Method of improving plant health
WO2008090474A3 (en) Production of rosmarinic acid from spearmint and uses thereof
BR112012002807A8 (pt) Derivados de 5-flúor-2-oxopirimidina-1(2h)-caboxilato, composição e processo para controle e prevenção de ataque fúngico em uma planta de ataque fúngico em uma planta
WO2012108635A3 (ko) 천궁 및 종대황의 혼합 생약 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물
WO2014056713A3 (en) Oral care composition
WO2013036610A3 (en) Compositions comprising mg53 and methods for the treatment and prevention of airway injury
WO2011080254A3 (en) Fungicide hydroximoyl-heterocycles derivatives
WO2012102581A3 (ko) 천궁 및 호장근의 혼합 생약 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물
WO2011102702A3 (en) Process for the preparation of oral solid dosage forms comprising valsartan
EP2661518A4 (en) Aqueous acid cleaning, corrosion and stain inhibiting compositions in the vapor phase comprising a blend of nitric and sulfuric acid
WO2014130313A3 (en) Methods and compositions relating to the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11842263

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013539765

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13885986

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011842263

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011842263

Country of ref document: EP